Similar articles

• Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.

  Kageyama S, Katsumoto T, Taniguchi K, Ismail SI, Shimmen T, Sasao F, Gao M, Owatari S, Wakamiya N, Tsuchie H, Ueda S, Shiraki K, Kurimura T. Kageyama S, et al. Acta Virol. 1996 Sep;40(4):195-200. Acta Virol. 1996. PMID: 9014009
• Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.

  Kmieciak D, Bolesta E, Naito T, Gzyl J, Kaneko Y, Kozbor D. Kmieciak D, et al. J Hum Virol. 2001 Nov-Dec;4(6):306-16. J Hum Virol. 2001. PMID: 12082397
• Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.

  Martin SJ, Vyakarnam A, Cheingsong-Popov R, Callow D, Jones KL, Senior JM, Adams SE, Kingsman AJ, Matear P, Gotch FM, et al. Martin SJ, et al. AIDS. 1993 Oct;7(10):1315-23. AIDS. 1993. PMID: 8267904
• HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.

  Fiorentini S, Giagulli C, Caccuri F, Magiera AK, Caruso A. Fiorentini S, et al. Pharmacol Ther. 2010 Dec;128(3):433-44. doi: 10.1016/j.pharmthera.2010.08.005. Epub 2010 Sep 8. Pharmacol Ther. 2010. PMID: 20816696 Review.
• Diagnosis of HIV-1 infection by detection of antibody IgG to HIV-1 in urine with ultrasensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) using recombinant proteins as antigens.

  Hashida S, Hashinaka K, Saitoh A, Takamizawa A, Shinagawa H, Oka S, Shimada K, Hirota K, Kohno T, Ishikawa S, et al. Hashida S, et al. J Clin Lab Anal. 1994;8(4):237-46. doi: 10.1002/jcla.1860080410. J Clin Lab Anal. 1994. PMID: 7523637 Review.